MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Clinical trial NCT01352273 · COMPLETED
Trial details
- NCT number
- NCT01352273
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-01
- Primary completion
- 2013-09-01
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.